| REVIEW ARTICLE |
|
| Year : 1995 | Volume
: 27
| Issue : 3 | Page : 142-151 |
Losartan, an angiotensin-II receptor antagonist, and a few of its congeners: A new therapeutic class in the management of Hypertension
MC Satia, TP Gandhi, RK Goyal
Correspondence Address:
M C Satia
 Source of Support: None, Conflict of Interest: None  | Check |
Angiotensin-II receptor antagonists are a new class of drugs for the management of hypertension. The major obstacle to their development, i.e., poor oral bioavailability, seems to be solved as losartan and TCV-116 are non-peptide antagonists and orally effective. These agents are new and promising antihypertensives, better than angiotensin converting enzyme (ACE) inhibitors in controlling blood pressure. The antihypertensive effect of losartan is enhanced when given in combination with hydrochlorthiazide. Losartan is very well tolerated in patients with mild, moderate and severe hypertension. Losartan decreases the mean urinary protein excretion and may have a beneficial effect on albuminuria in patients with diabetes. The uricosuric effect of losartan may be beneficial as many hypertensive patients are hyperuricemic. Unlike with ACE inhibitors, the adjustment in losartan dosage is not needed in the patients with renal insufficiency. TCV-116, another angiotensin-II antagonist, is highly potent and long-acting. Apart from its antihypertensive effects, TCV-116 also prevented left ventricular hypertrophy induced by high fructose diet in spontaneously hypertensive rats. Results of the studies on losartan and other agents indicate that they would certainly acquire a commanding position in the treatment of hypertension.
[PDF]*
|
